China Resources Double-Crane Pharmaceutical Co.,Ltd.: history, ownership, mission, how it works & makes money

From its roots in Beijing in 1939 to a modern pharmaceutical group with a controlling stake held 60.24% by China Resources Pharmaceutical Group, China Resources Double-Crane Pharmaceutical Co., Ltd. has grown through strategic deals- including the 2024 acquisition of CR Zizhu and the 2023 purchase of Guizhou Tianan-while reporting historical scale like roughly US$600 million in annual sales back in 2006; today its operations span GMP-certified manufacturing, over 200 patents, a reported RMB 500 million R&D investment in 2022 and a 99.5% GMP audit compliance rate, and its market footprint and balance sheet are reflected in a December 2025 stock price of CNY 18.19 and a market capitalization near CNY 19.17 billion-with new product milestones in 2025 including clinical trial approval for J002 and GMP clearance for a new solid-dosage workshop, plus a push to lift international sales from 4% in 2022 toward a 10% target by 2025, all of which frame a complex, acquisition-driven business model focused on women's health, blood products and both traditional and modern therapeutics that this article will unpack in detail

China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS): Intro

• 1939: Company founding.
• 2006: Reported annual sales of approximately US$600 million; held controlling stakes in 17 subsidiaries and equity interests in 7 other companies across major Chinese cities.
• 2023: Acquired Guizhou Tianan Pharmaceutical Co., Ltd., strengthening blood products marketing and distribution capabilities.
• 2024: Acquired 100% equity interest in CR Zizhu, marking entry into the women's health sector and expanding the product portfolio.
• 2025: Subsidiary China Resources Purple Bamboo Pharmaceutical Co., Ltd. received clinical trial approval for J002 (dry eye treatment).
• 2025: China Resources Double-Crane Pharmaceutical Limin Pharmaceutical (Jinan) Co., Ltd., passed drug GMP compliance inspection for its new solid dosage form workshop.

• Listed on Shanghai Stock Exchange (600062.SS) under the China Resources umbrella.
• Group structure features multiple subsidiaries focused on R&D, manufacturing, blood products, traditional Chinese medicine, OTC and hospital-market pharmaceuticals.
• Post-2024 strategic moves emphasize consolidation of specialty segments (women's health, blood products) through full acquisitions.

• Mission: Develop and deliver clinically effective, quality pharmaceutical products for hospitals and retail markets in China and selected export markets.
• Strategic priorities: product diversification (including women's health and ophthalmology), compliance with GMP/clinical standards, and expanding sales & marketing reach across provincial channels.

• R&D & Clinical: In-house and subsidiary-led clinical programs (e.g., J002 dry eye program approved for trials in 2025).
• Manufacturing: Multiple production facilities; recent GMP compliance for a new solid dosage workshop (2025) enhances capacity for oral solid forms.
• Acquisitions & Portfolio Expansion: Strategic M&A to acquire capabilities and market access (Guizhou Tianan for blood products, CR Zizhu for women's health).
• Sales & Distribution: Hospital and retail channels, regional sales teams, and partnerships with local distributors.

• Hospital-prescribed drugs (including injectables and blood products).
• Retail/OTC pharmaceuticals and consumer health products.
• Contract manufacturing and licensing revenues from partnerships.
• New product launches and lifecycle sales (specialty products like women's health and ophthalmology expected to increase margins over time).

China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS): History

• Ownership structure: as of December 2024, China Resources Pharmaceutical Group Limited indirectly holds 60.24% of the company.
• 2024: acquired 100% equity interest in CR Zizhu (a wholly-owned Group subsidiary), consolidating pipeline and manufacturing capabilities.
• 2023: acquired Guizhou Tianan Pharmaceutical Co., Ltd. from CR Boya Bio-pharmaceutical, broadening geographic and product reach.
• 2025: subsidiary China Resources Purple Bamboo Pharmaceutical Co., Ltd. received clinical trial approval for J002 (first-in-company clinical asset milestone).
• 2025: subsidiary China Resources Double-Crane Pharmaceutical Limin Pharmaceutical (Jinan) Co., Ltd. passed drug GMP compliance inspection, supporting commercial production scale-up.

• Business model: manufacture and sell active pharmaceutical ingredients (APIs) and finished formulations, supply hospital and retail channels, and develop/advance clinical-stage drugs through subsidiaries.
• How it makes money: revenue from commercial API and finished-dose sales, margin improvements via GMP-compliant scale-up, and long-term value creation from clinical asset progression (e.g., J002).
• Strategic effect of recent moves: acquisitions and compliance milestones have diversified product lines, improved manufacturing capacity, and positioned the firm to capture higher-margin innovative drug opportunities.

China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS): Ownership Structure

• Provide high-quality pharmaceutical products to improve public health.
• Drive innovation in R&D across traditional Chinese medicine and modern pharmaceuticals.
• Maintain and continuously strengthen Good Manufacturing Practice (GMP) standards for safety and efficacy.
• Expand international presence with target markets in Asia and Europe.
• Enhance capabilities in women's health through strategic acquisitions and product development.
• Adapt to evolving healthcare needs by developing treatments across multiple medical conditions.

• R&D: In-house research centers focus on TCM formulations, small-molecule drugs, and women's health compounds; pipeline stages from preclinical through registration.
• Manufacturing: Multiple GMP-certified production lines producing oral formulations, injectables, and TCM preparations; contract manufacturing for select partners.
• Sales & Distribution: Domestic hospital and retail pharmacy channels plus growing export channels to Asia and selected European partners.
• Acquisitions & Partnerships: Targeted deals to acquire specialty portfolios (women's health) and to gain regulatory/market access in overseas markets.

• Product sales (retail and hospital channels): core revenue driver.
• Contract manufacturing and toll production services.
• Licensing and tech transfer fees for proprietary formulations and production know-how.
• Export sales to regional partners in Asia and initial entry to European distributors.

• China Resources Group (State-owned conglomerate): majority/controlling stake (approx. 40-45%).
• Free float (A-share public investors): ~40-50%.
• Institutional investors and strategic partners (includes domestic pharma funds and long-only institutional holders): remainder.

• Increase women's-health portfolio revenue from RMB 500 million by 2026 via M&A and new product launches.
• Grow export share from ~7% to ~15% of revenue by 2026 through Asia-Europe channel development.
• Raise R&D investment to ~5% of revenue within three years to accelerate pipeline progression.

China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS): Mission and Values

• Manufacturing: Operates multiple manufacturing facilities across China, all maintained under Good Manufacturing Practice (GMP) standards to ensure product safety and regulatory compliance.
• Research & Development: Invests significantly in R&D to fuel new product development-R&D expenditure was approximately RMB 500 million in 2022.
• Intellectual Property: Holds over 200 patents covering innovative drug formulations and delivery systems to protect and commercialize its innovations.
• Subsidiaries & Pipeline: Subsidiaries such as China Resources Purple Bamboo Pharmaceutical Co., Ltd. focus on specialty development projects, including J002 for dry eye.
• Quality & Compliance: Emphasizes rigorous quality assurance, achieving a 99.5% compliance rate during GMP audits as of 2022.
• Distribution & Markets: Expands internationally through partnerships with local distributors in over 15 countries to increase market reach and access.

• Manufacture and sale of finished pharmaceuticals and active pharmaceutical ingredients (APIs) to domestic and international markets.
• Commercialization of proprietary formulations and delivery systems protected by its patent portfolio.
• Licensing and collaboration revenues from partnerships and subsidiary-developed therapies (e.g., development-stage assets like J002).
• Contract manufacturing and toll-manufacturing services leveraging GMP-certified facilities.

• Scale manufacturing capacity while maintaining high GMP compliance to serve both domestic and export markets.
• Prioritize R&D funding to advance proprietary candidates and strengthen the patent portfolio.
• Leverage distributor partnerships to accelerate international commercialization and local market penetration.

China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS): How It Works

• Primary revenue streams: manufacturing and sale of over-the-counter (OTC) drugs, prescription medicines, and traditional herbal products.
• Distribution footprint: wide domestic network (hospitals, pharmacies, retail chains) with growing export channels.
• Product mix: established name-brand consumer healthcare lines plus hospital-supply prescription portfolios and proprietary herbal formulations.
• Quality & compliance: enterprise-wide Good Manufacturing Practice (GMP) certification programs and regulatory compliance that support market access and pricing power.

• Manufacturing scale: in-house production lowers COGS and allows margin capture across OTC and Rx product lines.
• Brand-driven retail sales: core branded OTC products sold via retail pharmacies and e-commerce generate recurring, higher-frequency revenue.
• Hospital tenders and institutional sales: prescription drugs sold through hospital procurement and distribution partners deliver larger-ticket, lower-frequency contracts.
• R&D-driven product pipeline: internal R&D and acquired product lines provide mid-term revenue uplift from new launches and reformulations.
• Mergers & acquisitions: targeted M&A (e.g., CR Zizhu, Guizhou Tianan) expands therapeutic coverage, production capacity and geographic reach.

• Domestic brand penetration: marketing and channel incentives to deepen shelf presence and repeat purchases.
• R&D and product innovation: new formulations, line extensions and improved delivery forms to capture premium pricing.
• M&A and licensing: acquisitions such as CR Zizhu and Guizhou Tianan Pharmaceutical Co., Ltd. broaden therapeutic areas and add manufacturing capacity, accelerating top-line growth.
• Export expansion: international sales were ~4% of revenue in 2022, with a company target to reach ~10% by 2025 via regulatory approvals and partnerships in Asia and emerging markets.
• Quality and regulatory compliance: continued investment in GMP and quality systems reduces recall risk and supports tender wins and hospital adoption.

• OTC portfolio: high-frequency consumer purchases with stable margins and scalable digital/retail distribution.
• Prescription drugs: larger contracts and hospital channel penetration yielding higher revenue per SKU despite longer sales cycles.
• Herbal & traditional medicines: differentiated products that leverage brand heritage and command loyalty in regional markets.
• Contract manufacturing & toll production: surplus manufacturing capacity used to provide third-party production revenue streams.

China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS): How It Makes Money

• Primary revenue streams: finished drugs (branded generics and specialty products), contract manufacturing (CMO), and distribution/service fees.
• Strategic growth drivers: R&D-driven new product launches, integration of CR Zizhu (acquired 2024) to deepen women's health portfolio, and international expansion targeting 10% of revenue by 2025.
• Quality & compliance: adherence to GMP standards and formal quality assurance strengthen market access and hospital procurement eligibility.

• Profit model: margin improvement depends on higher-mix specialty and export sales, cost control in manufacturing, and synergies from acquisitions.
• Risks & challenges: short-term pressure on revenues/profits (9M 2025), pricing and reimbursement policies, and competition in generics.
• Outlook: R&D pipeline, CR Zizhu integration, GMP-backed quality positioning, and the push to grow international sales support medium‑term revenue diversification.